Stockscreener 앱 받기
4.77
6.84%
-0.35
시간 외 거래:
4.77
Pepgen Inc 주식(PEPG)의 최신 뉴스
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - PR Newswire
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PEPG SEC FilingsPepGen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
COMMODORE CAPITAL LP Acquires Additional Shares in PepGen Inc - GuruFocus
Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - FinancialContent
How much upside is left in PepGen (PEPG)? Wall Street analysts think 75.44% - MSN
Boxer Capital Management LLC Invests $1.16 Million in PepGen, Inc. $PEPG - MarketBeat
Commodore Capital LP Invests $10.89 Million in PepGen, Inc. $PEPG - MarketBeat
FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial - Sahm
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Aug Volume: Is PepGen Inc stock a smart retirement pickPrice Action & Technical Pattern Recognition Alerts - baoquankhu1.vn
PepGen falls 20% despite earnings beat on FDA hold concerns By Investing.com - Investing.com Nigeria
Commodore Capital discloses 5.1% stake in PepGen (PEPG) - Stock Titan
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
PepGen CEO McArthur sells $32875 in shares By Investing.com - Investing.com Nigeria
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com Nigeria
PepGen unveils new research at MDA2026 poster session - Traders Union
Research Analysts Offer Predictions for PepGen Q1 Earnings - MarketBeat
Profit Review: Can PepGen Inc. stock double in the next year2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Momentum: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEARTrade Entry Summary & Short-Term Trading Alerts - baoquankhu1.vn
PepGen CEO McArthur sells $32875 in shares - Investing.com
Surprises Report: How does PepGen Inc correlate with NasdaqJuly 2025 PreEarnings & AI Driven Stock Reports - baoquankhu1.vn
PepGen (PEPG) CFO’s 2,084-share automatic sale covers RSU tax withholding - Stock Titan
PepGen (PEPG) CEO share sale covers RSU tax withholding obligations - Stock Titan
Grocery Outlet posts downbeat Q4 earnings, joins SES AI, PepGen and other big stocks moving lower in Thursday's pre-market session - MSN
Grocery Outlet Posts Downbeat Q4 Earnings, Joins SES AI, PepGen And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Stifel reiterates Buy on PepGen stock amid partial clinical hold By Investing.com - Investing.com Australia
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - wjfw.com
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
PepGen Still On Track For PGN-EDODM1 Readouts Despite FDA Partial Hold - Citeline News & Insights
PepGen: Stock Slides On FDA Study HoldI'm Firmly On The Sidelines (NASDAQ:PEPG) - Seeking Alpha
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA - BioPharma Dive
Stifel reiterates Buy on PepGen stock amid partial clinical hold - Investing.com Nigeria
PepGen: Clinical and Safety Uncertainties, FDA Partial Hold, and Valuation Gap Support Underperform Rating - TipRanks
PepGen stock slides on FDA partial hold (PEPG:NASDAQ) - Seeking Alpha
PepGen Updates EDO Platform and DM1 Program Outlook - TipRanks
PepGen falls 20% despite earnings beat on FDA hold concerns - Investing.com India
Why Is PepGen Stock Falling Thursday?PepGen (NASDAQ:PEPG) - Benzinga
FDA places partial clinical hold on PepGen’s DM1 trial By Investing.com - Investing.com Canada
US FDA puts partial clinical hold on PepGen’s muscle disease drug trial - 1470 & 100.3 WMBD
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - PharmiWeb.com
PepGen Announces Regulatory Updates on FREEDOM2 - pharmiweb.com
Stocks to Watch : Broadcom, StubHub, PepGen, Veeva Systems - marketscreener.com
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com South Africa
PepGen reports Q4 EPS (27c), consensus (39c) - TipRanks
PepGen announce FDA placed partial clinical hold on Phase 2 trial of PGN-EDODM1 - TipRanks
PepGen's Phase 2 Trial of Drug to Treat Multisystem Disorder Placed on Hold by US FDA - marketscreener.com
PepGen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
1.20%
0.06%
자본화:
|
볼륨(24시간):